Comparative Pharmacology
Head-to-head clinical analysis: CLOFARABINE versus NIPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFARABINE versus NIPENT.
CLOFARABINE vs NIPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
None Documented
None Documented
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateClofarabine + Deslanoside
"Clofarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateClofarabine + Acetyldigitoxin
"Clofarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent